Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle

US6060587A · kind A · utility

Assignee

• The Trustees of the University of Pennsylvania · US

Inventors

• David B. Weiner · Yeadon, US
• Velpandi Ayyavoo · Pittsburgh, US
• Sundarasamy Mahalingam · Birmingham, US
• Mamata Patel · Hoboken, US

Key dates

• Filing date: Oct 10, 1997
• Grant date: May 9, 2000
• Expiry date: Oct 10, 2017

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to substantially pure human Vpr Interacting Protein (hVIP), and fragments thereof. Also disclosed are isolated nucleic acid molecules that encode hVIP, or a fragment thereof; nucleic acid probes and primers directed to nucleic acid molecules that encode hVIP, or a fragment thereof; oligonucleotide molecules that consist of a nucleotide sequence complementary to a portion of the nucleotide sequence that encodes hVIP; vectors comprising nucleic acid molecules encoding hVIP; recombinant expression vectors that comprise nucleic acid sequences that encode hVIP; host cells that comprise recombinant expression vectors which include nucleic acid sequences that encode hVIP; genetic therapy vectors comprising nucleic acid molecules encoding hVIP; isolated antibody which binds to an epitope on hVIP; pharmaceutical compositions comprising a pharmaceutically acceptable carrier and nucleic acid molecules complementary to a portion of hVIP; methods of making hVIP; and methods of inhibiting expression of hVIP oligonucleotides complementary to a portion of the nucleotide sequence that encodes hVIP.